Jingxia Li Selected Research

isorhapontigenin

11/2021	Isorhapontigenin (ISO) inhibits EMT through FOXO3A/METTL14/VIMENTIN pathway in bladder cancer cells.
1/2020	Isorhapontigenin (ISO) inhibits stem cell-like properties and invasion of bladder cancer cell by attenuating CD44 expression.
9/2018	ISO, via Upregulating MiR-137 Transcription, Inhibits GSK3β-HSP70-MMP-2 Axis, Resulting in Attenuating Urothelial Cancer Invasion.
1/2018	Transcriptional and post-transcriptional upregulation of p27 mediates growth inhibition of isorhapontigenin (ISO) on human bladder cancer cells.
7/2016	Isorhapontigenin (ISO) Inhibits Invasive Bladder Cancer Formation In Vivo and Human Bladder Cancer Invasion In Vitro by Targeting STAT1/FOXO1 Axis.
3/2016	Induction of miR-137 by Isorhapontigenin (ISO) Directly Targets Sp1 Protein Translation and Mediates Its Anticancer Activity Both In Vitro and In Vivo.
1/2016	SESN2/sestrin 2 induction-mediated autophagy and inhibitory effect of isorhapontigenin (ISO) on human bladder cancers.
1/2016	Isorhapontigenin suppresses growth of patient-derived glioblastoma spheres through regulating miR-145/SOX2/cyclin D1 axis.
5/2014	Isorhapontigenin (ISO) inhibited cell transformation by inducing G0/G1 phase arrest via increasing MKP-1 mRNA Stability.
8/2013	Cyclin d1 downregulation contributes to anticancer effect of isorhapontigenin on human bladder cancer cells.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Jingxia Li Research Topics

Disease

63	Neoplasms (Cancer) 01/2022 - 10/2002
31	Urinary Bladder Neoplasms (Bladder Cancer) 12/2021 - 10/2012
20	Carcinogenesis 01/2017 - 05/2002
8	Lung Neoplasms (Lung Cancer) 01/2021 - 08/2006
7	Neoplasm Metastasis (Metastasis) 12/2019 - 04/2012
6	Inflammation (Inflammations) 06/2011 - 11/2002
5	Pneumonia (Pneumonitis) 10/2016 - 02/2009
3	Hypoxia (Hypoxemia) 10/2012 - 01/2004
3	Skin Neoplasms (Skin Cancer) 01/2008 - 04/2006
2	Carcinoma (Carcinomatosis) 06/2017 - 01/2015
2	Esophageal Neoplasms (Esophageal Cancer) 01/2015 - 06/2005
2	Colonic Neoplasms (Colon Cancer) 03/2014 - 01/2006
2	Leukemia 02/2014 - 09/2013
1	Uterine Cervicitis (Cervicitis) 01/2022
1	Graft vs Host Disease (Graft-Versus-Host Disease) 01/2022
1	Infections 01/2022
1	Necrosis 01/2022
1	Papillomavirus Infections 01/2022
1	Liver Neoplasms (Liver Cancer) 01/2021
1	Endometrioid Carcinoma 01/2020
1	Glioma (Gliomas) 01/2020
1	Communicable Diseases (Infectious Diseases) 05/2019
1	Lymphatic Metastasis 01/2019
1	Cholangiocarcinoma 01/2019
1	Hepatocellular Carcinoma (Hepatoma) 08/2018
1	Endometrial Neoplasms (Endometrial Cancer) 08/2018
1	Colorectal Neoplasms (Colorectal Cancer) 01/2018
1	Uterine Cervical Neoplasms (Cancer of the Cervix) 10/2017

Drug/Important Bio-Agent (IBA)

21	Proteins (Proteins, Gene)FDA Link 12/2021 - 08/2005
11	isorhapontigeninIBA 11/2021 - 10/2012
11	Cyclin D1IBA 01/2020 - 07/2006
10	arseniteIBA 09/2013 - 10/2005
9	CarcinogensIBA 07/2016 - 05/2004
8	X-Linked Inhibitor of Apoptosis ProteinIBA 12/2019 - 05/2011
8	Transcription Factors (Transcription Factor)IBA 09/2014 - 10/2002
8	Transcription Factor AP-1 (Transcription Factor AP 1)IBA 01/2007 - 10/2002
7	Biological ProductsIBA 01/2020 - 05/2011
7	NickelIBA 10/2016 - 10/2002
6	Small Interfering RNA (siRNA)IBA 12/2019 - 11/2006
6	Messenger RNA (mRNA)IBA 12/2019 - 09/2014
5	NF-kappa B (NF-kB)IBA 01/2007 - 10/2002
4	cheliensisin AIBA 11/2018 - 09/2013
4	LactonesIBA 11/2018 - 09/2013
4	Cyclooxygenase 2 (Cyclooxygenase-2)IBA 06/2011 - 07/2006
4	Epoxy Compounds (Epoxides)IBA 01/2007 - 04/2004
4	Benzo(a)pyreneIBA 01/2007 - 05/2004
3	Biomarkers (Surrogate Marker)IBA 01/2020 - 01/2015
3	MicroRNAs (MicroRNA)IBA 01/2020 - 01/2017
3	Matrix Metalloproteinases (MMPs)IBA 01/2020 - 11/2017
3	Phosphoric Monoester Hydrolases (Phosphatases)IBA 01/2019 - 08/2005
3	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 08/2015 - 03/2006
3	CytokinesIBA 01/2015 - 11/2002
3	rho-Specific Guanine Nucleotide Dissociation InhibitorsIBA 04/2012 - 05/2011
2	Long Noncoding RNAIBA 09/2020 - 08/2018
2	ChlA-FIBA 01/2020 - 11/2018
2	Pharmaceutical PreparationsIBA 01/2019 - 01/2016
2	Phosphotransferases (Kinase)IBA 01/2019 - 10/2018
2	Leucine-Rich Repeat ProteinsIBA 01/2019 - 10/2018
2	NucleolinIBA 01/2018 - 02/2015
2	NitrosaminesIBA 01/2018 - 07/2016
2	StilbenesIBA 07/2016 - 08/2013
2	Therapeutic UsesIBA 05/2014 - 02/2014
2	Cyclin-Dependent Kinases (cdk Proteins)IBA 09/2013 - 08/2010
2	Ubiquitin-Protein Ligases (Ubiquitin-Protein Ligase)IBA 07/2013 - 01/2012
2	EnzymesIBA 06/2011 - 09/2007
2	ArsenicIBA 02/2009 - 04/2007
2	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2006 - 01/2006
2	Phosphatidylinositol 3-Kinase (1 Phosphatidylinositol 3 Kinase)IBA 08/2005 - 01/2004
1	Interleukin-4 (Interleukin 4)IBA 01/2022
1	DNA (Deoxyribonucleic Acid)IBA 01/2022
1	NeuropeptidesIBA 01/2022
1	Vasoactive Intestinal Peptide (VIP (Vasoactive Intestinal Peptide))IBA 01/2022
1	VimentinIBA 11/2021
1	Apoptosis Regulatory ProteinsIBA 12/2019
1	SeleniumIBA 11/2019
1	TubulinIBA 11/2019
1	Competitive Endogenous RNAIBA 06/2019
1	C-Reactive ProteinIBA 05/2019
1	Immune Checkpoint InhibitorsIBA 03/2019
1	Programmed Cell Death 1 ReceptorIBA 03/2019
1	LigandsIBA 03/2019
1	B7-H1 AntigenIBA 03/2019
1	Biocompatible Materials (Biomaterials)IBA 01/2019
1	PerforinIBA 01/2019
1	Tissue Inhibitor of Metalloproteinase-2IBA 01/2019
1	ChitosanIBA 01/2019
1	Inhibitor of Apoptosis ProteinsIBA 11/2017
1	benzothiazoleIBA 10/2017
1	Cadherins (E-Cadherin)IBA 10/2017
1	ButylhydroxybutylnitrosamineIBA 06/2017
1	E2F1 Transcription FactorIBA 01/2017
1	HSP70 Heat-Shock Proteins (Heat-Shock Protein 70)IBA 01/2017
1	Antineoplastic Agents (Antineoplastics)IBA 01/2017
1	Beclin-1IBA 10/2016

Therapy/Procedure

11	Therapeutics 01/2021 - 03/2014
3	Immunotherapy 01/2021 - 01/2019
2	Cell- and Tissue-Based Therapy (Cell Therapy) 11/2019 - 01/2019
2	Radiotherapy 01/2019 - 01/2015
1	Liver Transplantation 01/2019
1	Drug Therapy (Chemotherapy) 01/2019